Elamin H Elbasha

Summary

Affiliation: Merck Research Laboratories
Country: USA

Publications

  1. ncbi Impact of vaccinating boys and men against HPV in the United States
    Elamin H Elbasha
    Health Economic Statistics, Biostatistics and Research Decision Sciences, Merck Research Laboratories, Merck and Co, Inc, UG1C 60, PO Box 1000, North Wales, PA 19454 1099, USA elamin
    Vaccine 28:6858-67. 2010
  2. ncbi A multi-type HPV transmission model
    Elamin H Elbasha
    Merck Research Laboratories, UG1C 60, PO Box 1000, North Wales, PA 19454 1099, USA
    Bull Math Biol 70:2126-76. 2008
  3. ncbi Cost-effectiveness of quadrivalent human papillomavirus (HPV) vaccination in Mexico: a transmission dynamic model-based evaluation
    Ralph P Insinga
    Department of Health Economic Statistics UG1C 60, Merck Research Laboratories, PO Box 1000, North Wales, PA 19454 1099, USA
    Vaccine 26:128-39. 2007
  4. ncbi Incidence, duration, and reappearance of type-specific cervical human papillomavirus infections in young women
    Ralph P Insinga
    Merck Research Laboratories, North Wales, PA 19454 10099, USA
    Cancer Epidemiol Biomarkers Prev 19:1585-94. 2010
  5. ncbi The cost effectiveness of a quadrivalent human papillomavirus vaccine (6/11/16/18) in Hungary
    Erik J Dasbach
    Health Economic Statistics, Biostatistics and Research Decision Sciences, Merck Research Laboratories, North Wales, PA 19454 1099, USA
    J Med Econ 13:110-8. 2010
  6. ncbi Age-based programs for vaccination against HPV
    Elamin H Elbasha
    Merck Research Laboratories, Merck and Co, Inc, NorthWales, PA, USA
    Value Health 12:697-707. 2009
  7. ncbi The cost-effectiveness of a quadrivalent human papillomavirus vaccine in Taiwan
    Erik J Dasbach
    Health Economic Statistics, Biostatistics and Research Decision Sciences, Merck Research Laboratories, North Wales, PA 19454 1099, USA
    Asian Pac J Cancer Prev 9:459-66. 2008
  8. ncbi Structural differences among cost-effectiveness models of human papillomavirus vaccines
    Ralph P Insinga
    Department of Health Economic Statistics, Merck Research Laboratories, North Wales, PA 19454 1099, USA
    Expert Rev Vaccines 7:895-913. 2008
  9. ncbi Epidemiologic natural history and clinical management of Human Papillomavirus (HPV) Disease: a critical and systematic review of the literature in the development of an HPV dynamic transmission model
    Ralph P Insinga
    Department of Health Economic Statistics, Merck Research Laboratories, North Wales, PA, USA
    BMC Infect Dis 9:119. 2009
  10. ncbi Incidence and duration of cervical human papillomavirus 6, 11, 16, and 18 infections in young women: an evaluation from multiple analytic perspectives
    Ralph P Insinga
    Department of Health Economic Statistics, Merck Research Laboratories, North Wales, PA 19454 1099, USA
    Cancer Epidemiol Biomarkers Prev 16:709-15. 2007

Collaborators

Detail Information

Publications13

  1. ncbi Impact of vaccinating boys and men against HPV in the United States
    Elamin H Elbasha
    Health Economic Statistics, Biostatistics and Research Decision Sciences, Merck Research Laboratories, Merck and Co, Inc, UG1C 60, PO Box 1000, North Wales, PA 19454 1099, USA elamin
    Vaccine 28:6858-67. 2010
    ..Vaccinating boys and men age 9-26 against all HPV 6/11/16/18-associated diseases provides substantial public health benefits and is cost-effective at commonly cited thresholds...
  2. ncbi A multi-type HPV transmission model
    Elamin H Elbasha
    Merck Research Laboratories, UG1C 60, PO Box 1000, North Wales, PA 19454 1099, USA
    Bull Math Biol 70:2126-76. 2008
    ....
  3. ncbi Cost-effectiveness of quadrivalent human papillomavirus (HPV) vaccination in Mexico: a transmission dynamic model-based evaluation
    Ralph P Insinga
    Department of Health Economic Statistics UG1C 60, Merck Research Laboratories, PO Box 1000, North Wales, PA 19454 1099, USA
    Vaccine 26:128-39. 2007
    ..S.) per quality-adjusted life year (QALY) gained for female vaccination strategies to approximately 16000 dollars /QALY for adding male vaccination with catch-up...
  4. ncbi Incidence, duration, and reappearance of type-specific cervical human papillomavirus infections in young women
    Ralph P Insinga
    Merck Research Laboratories, North Wales, PA 19454 10099, USA
    Cancer Epidemiol Biomarkers Prev 19:1585-94. 2010
    ..We describe the incidence and duration of cervical human papillomavirus (HPV) infection episodes along with the risk of infection reappearance following a period of nondetection...
  5. ncbi The cost effectiveness of a quadrivalent human papillomavirus vaccine (6/11/16/18) in Hungary
    Erik J Dasbach
    Health Economic Statistics, Biostatistics and Research Decision Sciences, Merck Research Laboratories, North Wales, PA 19454 1099, USA
    J Med Econ 13:110-8. 2010
    ....
  6. ncbi Age-based programs for vaccination against HPV
    Elamin H Elbasha
    Merck Research Laboratories, Merck and Co, Inc, NorthWales, PA, USA
    Value Health 12:697-707. 2009
    ..Answering the question of which age groups are appropriate to target for catch-up vaccination with the newly licensed quadrivalent HPV vaccine (types 6/11/16/18) will be important for developing vaccine policy recommendations...
  7. ncbi The cost-effectiveness of a quadrivalent human papillomavirus vaccine in Taiwan
    Erik J Dasbach
    Health Economic Statistics, Biostatistics and Research Decision Sciences, Merck Research Laboratories, North Wales, PA 19454 1099, USA
    Asian Pac J Cancer Prev 9:459-66. 2008
    ....
  8. ncbi Structural differences among cost-effectiveness models of human papillomavirus vaccines
    Ralph P Insinga
    Department of Health Economic Statistics, Merck Research Laboratories, North Wales, PA 19454 1099, USA
    Expert Rev Vaccines 7:895-913. 2008
    ....
  9. ncbi Epidemiologic natural history and clinical management of Human Papillomavirus (HPV) Disease: a critical and systematic review of the literature in the development of an HPV dynamic transmission model
    Ralph P Insinga
    Department of Health Economic Statistics, Merck Research Laboratories, North Wales, PA, USA
    BMC Infect Dis 9:119. 2009
    ..S. population context; (2) Identify areas where additional studies are particularly needed...
  10. ncbi Incidence and duration of cervical human papillomavirus 6, 11, 16, and 18 infections in young women: an evaluation from multiple analytic perspectives
    Ralph P Insinga
    Department of Health Economic Statistics, Merck Research Laboratories, North Wales, PA 19454 1099, USA
    Cancer Epidemiol Biomarkers Prev 16:709-15. 2007
    ..To estimate the incidence and duration of cervical human papillomavirus (HPV)-6, HPV-11, HPV-16, and HPV-18 infections in a population of young American women...
  11. ncbi Model for assessing human papillomavirus vaccination strategies
    Elamin H Elbasha
    Merck Research Laboratories, North Wales, Pennsylvania 19454 1099, USA
    Emerg Infect Dis 13:28-41. 2007
    ..The ICER of this strategy was $45,056 per QALY...
  12. ncbi Global stability of equilibria in a two-sex HPV vaccination model
    Elamin H Elbasha
    Merck Research Laboratories, UG1C 60, P O Box 1000, North Wales, PA 19454 1099, USA
    Bull Math Biol 70:894-909. 2008
    ..If the effective reproduction number is less than unity, the infection-free equilibrium is globally asymptotically stable, and HPV will be eliminated...
  13. ncbi Assessment of the cost-effectiveness of a quadrivalent HPV vaccine in Norway using a dynamic transmission model
    Erik J Dasbach
    Health Economic Statistics, Biostatistics and Research Decision Sciences, Merck Research Laboratories, UG1C 60, PO Box 1000, North Wales, PA 19454 1099, USA
    Expert Rev Pharmacoecon Outcomes Res 8:491-500. 2008
    ....